A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01578772|
Recruitment Status : Completed
First Posted : April 17, 2012
Results First Posted : December 8, 2014
Last Update Posted : December 8, 2014
This research study is to see whether blood vessel function, an early sign of heart disease, improves in HIV-infected men and women who take telmisartan for 12 weeks. The investigators will be looking at how a blood vessel in the arm, called the brachial artery, changes in response to stress before and after taking telmisartan. To determine how well the blood vessel functions, the investigators will be using an ultrasound machine.
Telmisartan is not an HIV medication. It is an FDA-approved medication designed to treat blood pressure, but has been shown to improve blood vessel function in HIV-negative people with and without high blood pressure. Telmisartan is made by Boehringer Ingelheim, and this trial is sponsored by The Campbell Foundation.
|Condition or disease||Intervention/treatment||Phase|
|Endothelial Dysfunction||Drug: Telmisartan||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Telmisartan and Flow-Mediated Dilatation in Older HIV-Infected Patients at Risk for Cardiovascular Disease|
|Study Start Date :||August 2012|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||March 2013|
80mg tablets po daily for 6 weeks
Other Name: Micardis
- 6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy [ Time Frame: 6 weeks (after baseline) ]Flow-mediated dilatation (FMD) testing of the brachial artery was performed for all participants on Telmisartan treatment at baseline and 6 weeks.
- 6-week Change in Maximum Relative Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy [ Time Frame: 6 weeks (after baseline) ]Flow-mediated dilatation (FMD) testing of the brachial artery was performed for all participants on Telmisartan treatment at baseline and 6 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01578772
|United States, California|
|UCLA CARE Center|
|Los Angeles, California, United States, 90035|
|Principal Investigator:||Jordan E. Lake, MD||University of California, Los Angeles|